U.S. Markets
Pfizer (PFE) acquires exclusive rights to commercialise obesity therapy in China and is to pay Hangzhou Sciwind Biosciences up to USD 495mln
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
